Aclidinium Bromide + Formoterol Fumarate

Aclidinium Bromide + Formoterol Fumarate is a fixed-dose combination inhalation therapy indicated for the long-term maintenance treatment of chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema. This combination helps improve lung function, reduce symptoms, and minimize the risk of exacerbations in adult patients.

✅ Approved & Common Indications

🌿 Chronic Obstructive Pulmonary Disease (COPD)

Indicated as a long-term, once-daily, maintenance bronchodilator treatment for:

• Chronic bronchitis
• Emphysema
• Mixed COPD phenotypes

It provides dual bronchodilation by combining a long-acting muscarinic antagonist (LAMA) with a long-acting β2-adrenergic agonist (LABA), improving airflow, relieving persistent symptoms such as breathlessness and cough, and enhancing overall quality of life in patients with moderate to severe COPD.

✅ Off-Label and Investigational Uses (Emerging Areas)

Though not officially approved, studies have explored its potential role in:

• Reducing COPD exacerbation frequency
• Improving exercise tolerance and daily symptom control
  These investigational uses should only be considered under specialist supervision.